Grifols, S.A. (GRFS) is a publicly traded company in the Healthcare — Drug Manufacturers - General industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions.
Is Grifols, S.A. stock overvalued or undervalued in 2026?
Grifols, S.A. (GRFS) trades at 16.4× earnings (P/E), below the median of the 249 healthcare companies over $2bn in Kaplio's universe. At the decade median (16.0×) $8 (-2 %); at its sector median (30.7×) $15 (+87 %).
Kaplio overview: Grifols, S.A.
Market cap $7B · 52 weeks $7.02 – $9.72 (16 % below the high) · P/E 16.4× · 2027 est. P/E 6.6× · Dividend 0.75 % · Next earnings November 2, 2026 · expected EPS $0.32 · Closing price, Oct 30 · accounts published Jul 28.
- Valuation: TTM P/E 16.4× (fairly priced).
- Business: ROIC 5 % (weak).
- Balance sheet: Net debt/EBITDA 4.9× (fragile).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
At the decade median (16.0×) $8 (-2 %); at its sector median (30.7×) $15 (+87 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 5.0 %, fails.
- 5y EPS growth −8.9 %, fails.
- Gross margin 35.7 %, fails.
- ROIC 5.5 %, fails.
- Net debt / EBITDA 4.9×, fails.
- FCF / Net Income 194.5 %, passes.
- P/E vs own 10y history 16.4×, passes.
Against its peers (reference peers) — Grifols, S.A.: P/E 16.4×; EV/EBITDA 8.3×; ROIC 5.5 %; $6.9B. Haemonetics Corporation (P/E 58.6×; EV/EBITDA 24.5×; ROIC 8.6 %; $5.4B), Bio-Rad Laboratories, Inc. (P/E 45.1×; EV/EBITDA 20.7×; ROIC 1.5 %; $10.0B), Bio-Techne Corporation (P/E 62.6×; EV/EBITDA 33.3×; ROIC 7.8 %; $11.4B).
Expensive or cheap against its last ten years?
P/E at each close: today 16.4× · median 16.0× · minimum 7.9× · maximum 75.4× · cheap below 14.2× · expensive above 20.5×. It has been cheaper than today 53% of the time over its last ten years.
Dividend
tight (only raised recently) · Yield 0.75 % (€0.18 per share in 2025) · Years raising it 1 · Free cash flow coverage 7.2× · With $1,000 invested today you'd collect $7.50 a year ($0.62 a month).
Profitability
| Return on Equity | 8.43% |
| Return on Invested Capital | 5.47% |
| Return on Assets | 2.25% |
| Gross Margin | 37.23% |
| Operating Margin | 16.66% |
| Net Margin | 6.09% |
Financial Health
| Debt / Equity | 1.54 |
| Current Ratio | 2.37 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 1.02 |
Price Performance
| 1 month | +10.81% |
| 3 months | +0.37% |
| Year-to-date | -13.37% |
| 1 year | -13.55% |
| 3 years | -13.00% |
| 5 years | -37.35% |
| 10 years | -44.52% |
Dividend History
Paid in the last 12 months: $0.1058 per share in 1 payments.
| Date | Amount |
|---|---|
| July 2, 2026 | $0.1058 |
| August 12, 2025 | $0.1758 |
| June 3, 2021 | $0.3598 |
| October 30, 2020 | $0.1432 |
| December 2, 2019 | $0.1697 |
| June 7, 2019 | $0.1323 |
| November 30, 2018 | $0.1746 |
| June 1, 2018 | $0.1928 |
| December 1, 2017 | $0.1625 |
| May 30, 2017 | $0.1225 |
Amounts adjusted for stock splits.
Related companies: TECH · ADMA · MRVI · ABT · BDX · BIO · HAE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of GRFS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks